Loading...
•
Dec 31, 2019
West Pharma Q4 2019 Earnings Report
West Pharma reported strong Q4 2019 sales and EPS growth, continuing a trend seen throughout the year.
Key Takeaways
West Pharmaceutical Services, Inc. announced its financial results for the fourth-quarter and full-year 2019. Fourth-quarter 2019 net sales of $470.6 million grew 11.4%, reported-diluted EPS of $0.84 increased 22%, and adjusted-diluted EPS of $0.82 increased 12%.
Fourth-quarter net sales grew 11.4% to $470.6 million.
Organic sales growth was 12.7%.
Reported-diluted EPS increased 22% to $0.84.
Adjusted-diluted EPS increased 12% to $0.82.
Revenue by Segment
Forward Guidance
The Company expects full-year 2020 net sales guidance to be in a range of $1.95 billion to $1.97 billion and reported-diluted EPS to be in the range of $3.45 to $3.55.
Positive Outlook
- Organic sales growth is expected to be in the range of 7% to 8%.
- Company expects full-year 2020 net sales guidance to be in a range of $1.95 billion to $1.97 billion.
- The Company expects full-year 2020 reported-diluted EPS to be in the range of $3.45 to $3.55.
- Full-year 2020 capital spending is expected to be approximately 7% of expected full-year 2020 net sales.
- Any tax benefits associated with stock-based compensation that we receive in 2020 would provide a positive adjustment to our full-year EPS guidance.
Challenges Ahead
- Net sales guidance includes an estimated headwind of $15 million for the full-year 2020 based on current foreign exchange rates.
- This includes an estimated headwind of approximately $0.04 based on current foreign currency exchange rates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...